Tibulizumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | BAFF |
Clinical data | |
Synonyms | LY 3090106 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C8934H13698N2398O2808S56 |
Molar mass | 201.4 g/mol |
Tibulizumab (LY 3090106) (INN[1]) is a humanized monoclonal antibody designed for the treatment of autoimmune diseases.
This drug was developed by Eli Lilly and Co.[2]
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.